在canvas和credence试验中,基线风险和脏intelX.dkd的纵向变化及其与脏结果的关联
Erik Moedt1, Steven G Coca2, Katherine Edwards3
1Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
Diabetes care
|November 11, 2025
概括
脏intelX.dkd生物标记得分改善了2型糖尿病患者慢性病 (CKD) 风险预测. 它还显示了对canagliflozin的治疗反应,有助于个性化护理.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 生物标志物研究 生物标志物研究
背景情况:
- 慢性病 (CKD) 影响了数以百万计的2型糖尿病患者.
- 准确的风险分层对于管理CKD进展至关重要.
- 当前的风险分类系统可能无法完全捕捉个体患者的风险.
研究的目的:
- 评估脏intelX.dkd生物标志物评分的预后和临床效用.
- 为了比较脏intelX.dkd与脏疾病改善全球结果 (KDIGO) 风险分类.
- 评估脏intelX.dkd对卡纳格利弗洛辛治疗的反应能力.
主要方法:
- 生物标志物 (TNFR-1,TNFR-2,KIM-1) 在2型糖尿病患者的血中测量,这些患者患有CKD G1-G3b.
- 计算了 kidneyintelX.dkd 的得分,并与 KDIGO 的风险水平进行了比较.
- 分析了与脏结果的关联以及卡纳格利弗洛辛治疗效应.
主要成果:
- kidneyintelX.dkd得分与KDIGO风险类别相关,但提供了改进的个人风险重新分类.
- 脏intelX.dkd得分独立预测脏结果,表现优于KDIGO分类.
- 卡纳格利弗洛辛降低了脏intelX.dkd得分,高风险患者的风险降低更大.
结论:
- kidneyintelX.dkd提供了超出2型糖尿病和CKD的临床因素的预后价值.
- 该得分反映了对卡纳格利弗洛辛的治疗反应,识别了潜在的受益者.
- kidneyintelX.dkd支持临床实践中的个性化风险评估和监测.
相关概念视频
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
238
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
238
01:25Chronic Kidney Disease I: Introduction
531
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
531
01:28Chronic Kidney Disease III: Interprofessional Care
316
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
316
01:22Acute Kidney Injury I: Introduction
500
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
500
01:29Acute Kidney Injury III: Clinical Manifestations
754
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
754
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
158
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
158